Humana (HUM) vs Natera (NTRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Natera (NTRA) has outperformed Humana (HUM) over the past year, gaining 137.9% versus a gain of 34.3%. Over five years, NTRA leads with a +261.9% price change compared with -10.1% for HUM. Natera is the larger company by market cap ($57.02 billion vs $47.61 billion), about 1.2 times the size.
Humana pays a dividend yielding 0.89%, while Natera does not currently pay one. Humana converts more of its revenue into profit, with a net margin of 0.9% versus -9.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUM | NTRA |
|---|---|---|
| Share price | $396.51 | $395.56 |
| Market cap | $47.61B | $57.02B |
| 1-day change | -1.92% | -1.27% |
| YTD return | +54.81% | +74.97% |
| 1-year return | +34.30% | +137.85% |
| 5-year return | -10.09% | +261.88% |
| P/E ratio (TTM) | 37.48 | — |
| Forward P/E | 23.90 | — |
| EPS (TTM) | $10.58 | $-1.35 |
| Dividend yield | 0.89% | 0.00% |
| Annual dividend | $3.54 | $0.00 |
| Revenue (latest FY) | $129.66B | $2.31B |
| Revenue growth (YoY) | +10.11% | +35.90% |
| Net income (latest FY) | $1.19B | $-208.16M |
| Operating margin | 2.09% | -13.44% |
| Net margin | 0.92% | -9.03% |
| 52-week high | $428.88 | $437.41 |
| 52-week low | $163.11 | $167.99 |
| Distance from 52-week high | -7.55% | -9.57% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +6.87% | -4.58% |
| Average volume | 1.23M | 1.42M |
| Shares outstanding | 120.08M | 144.14M |
| Employees | 67,060 | 6,135 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NTRA has outperformed HUM by 103.6 percentage points over the past year.
- Humana is more profitable, keeping 0.9 cents of every revenue dollar as net income versus -9.0 cents for Natera.
- Natera grew revenue faster in its latest fiscal year (+35.90% vs +10.11%).
About Humana
HUM stock →Humana Inc. provides medical and specialty insurance products in the United States.
Health Care · Medical Specialities · 67,060 employees
About Natera
NTRA stock →Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
Health Care · Medical Specialities · 6,135 employees
HUM vs NTRA FAQ
Which is bigger, Humana or Natera?
Natera (NTRA) is larger, with a market capitalization of $57.02B compared with $47.61B for Humana (HUM).
Which stock has performed better over the past year, HUM or NTRA?
NTRA returned +137.85% over the past 12 months, compared with +34.30% for HUM (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Humana or Natera?
Humana pays a dividend yielding 0.89%, while Natera does not currently pay a regular dividend.
Are Humana and Natera in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.